Format

Send to

Choose Destination
See comment in PubMed Commons below
Neurology. 2016 Jun 14;86(24):2251-7. doi: 10.1212/WNL.0000000000002767. Epub 2016 May 18.

Pregnancy outcome following maternal exposure to pregabalin may call for concern.

Author information

1
From STIS (Swiss Teratogen Information Service) and Division of Clinical Pharmacology (U.W., A.P., L.E.R., J.B., T.B.), Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; BELTIS Rabin Medical Center and Sackler School of Medicine (P.M.), University of Tel-Aviv, Israel; Materno-Fetal and Obstetrics Research Unit (D.B.) and Institute of Social and Preventive Medicine (IUMSP) (V.R.), Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Centre Régional de Pharmacovigilance (N.B., T.V.), Hospices Civils de Lyon, France; UKTIS (L.M.Y.), Regional Drug and Therapeutics Centre, Newcastle upon Tyne Hospitals NHS Trust, UK; Centro di Riferimento Regionale di Tossicologia Perinatale (A.P.), Azienda Ospedaliero Universitaria Careggi, Florence, Italy; HUCH Teratology Information Service (M.E.), HUCH Emergency Care, Helsinki, Finland; Poison Control (G.E.), Bergamo, Italy; TIS (L.C.d.V.), Netherlands Pharmacovigilance Centre Lareb, Den Bosch; Unit of Pharmacotherapy & Pharmaceutical Care, Department of Pharmacy, University of Groningen, the Netherlands; Centre de Pharmacovigilance de Tours (A.-P.J.-B.), CHRU, Tours, France; and Department of Pharmacology (M.K.), Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey. ursula.winterfeld@chuv.ch.
2
From STIS (Swiss Teratogen Information Service) and Division of Clinical Pharmacology (U.W., A.P., L.E.R., J.B., T.B.), Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; BELTIS Rabin Medical Center and Sackler School of Medicine (P.M.), University of Tel-Aviv, Israel; Materno-Fetal and Obstetrics Research Unit (D.B.) and Institute of Social and Preventive Medicine (IUMSP) (V.R.), Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Centre Régional de Pharmacovigilance (N.B., T.V.), Hospices Civils de Lyon, France; UKTIS (L.M.Y.), Regional Drug and Therapeutics Centre, Newcastle upon Tyne Hospitals NHS Trust, UK; Centro di Riferimento Regionale di Tossicologia Perinatale (A.P.), Azienda Ospedaliero Universitaria Careggi, Florence, Italy; HUCH Teratology Information Service (M.E.), HUCH Emergency Care, Helsinki, Finland; Poison Control (G.E.), Bergamo, Italy; TIS (L.C.d.V.), Netherlands Pharmacovigilance Centre Lareb, Den Bosch; Unit of Pharmacotherapy & Pharmaceutical Care, Department of Pharmacy, University of Groningen, the Netherlands; Centre de Pharmacovigilance de Tours (A.-P.J.-B.), CHRU, Tours, France; and Department of Pharmacology (M.K.), Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey.

Abstract

OBJECTIVE:

To investigate pregnancy outcomes following maternal use of pregabalin.

METHODS:

This multicenter, observational prospective cohort study compared pregnancy outcomes in women exposed to pregabalin with those of matched controls (not exposed to any medications known to be teratogenic or to any antiepileptic drugs). Teratology Information Services systematically collected data between 2004 and 2013.

RESULTS:

Data were collected from 164 exposed pregnancies and 656 controls. A significantly higher major birth defect rate in the pregabalin group was observed after exclusion of chromosomal aberration syndromes, and when cases with exposure during first trimester of pregnancy were analyzed separately (7/116 [6.0%] vs 12/580 [2.1%]; odds ratio 3.0, 95% confidence interval 1.2-7.9, p = 0.03). The rate of live births was lower in the pregabalin group (71.9% vs 85.2%, p < 0.001), primarily due to a higher rate of both elective (9.8% vs 5.0%, p = 0.02) and medically indicated (5.5% vs 1.8%, p = 0.008) pregnancy terminations. In the Cox proportional cause specific hazards model, pregabalin exposure was not associated with a significantly higher risk of spontaneous abortion.

CONCLUSIONS:

This study demonstrated a signal for increased risk of major birth defects after first trimester exposure to pregabalin. However, several limitations such as the small sample size, differences across groups in maternal conditions, and concomitant medication exposure exclude definitive conclusions, so these results call for confirmation through independent studies.

PMID:
27194385
DOI:
10.1212/WNL.0000000000002767
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center